Europe Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

List of Tables

The Europe lung cancer therapy market was valued at US$ 9,919.66 million in 2022 and is expected to reach US$ 25,548.74 million by 2030; it is estimated to grow at a CAGR of 12.6% from 2022 to 2030.

Government Initiatives for Screening and Treatment of Lung Cancer Drive Europe Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. The Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Europe lung cancer therapy market.

Europe Lung Cancer Therapy Market Overview

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly.

The German National Cancer Plan designates organ cancer centers (lung cancer centers), oncology centers, and comprehensive cancer centers to offer general oncologic care in Germany. As of 2020, 64 lung cancer centers at 79 institutions were certified nationwide. Rise in the incidence of lung cancer and an increase in the number of lung cancer centers across Germany are fueling the growth of the market.

Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Therapy Market Segmentation

The Europe lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany dominated the Europe lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Europe lung cancer therapy market.

Product Code: BMIRE00029871

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Europe Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Lung Cancer Therapy Market - Europe Market Analysis

5.1 Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 Europe Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Lung Cancer Therapy Market - Country Analysis

9.1.1 Europe Lung Cancer Therapy Market, by Country
- 9.1.1.1 UK
  - 9.1.1.1.1 Overview
  - 9.1.1.1.2 UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.1.3 UK: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.1.3.1 UK: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.1.4 UK: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.1.5 UK: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.2 Germany
  - 9.1.1.2.1 Overview
  - 9.1.1.2.2 Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.2.3 Germany: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.2.3.1 Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.2.4 Germany: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.2.5 Germany: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.3 France
  - 9.1.1.3.1 Overview
  - 9.1.1.3.2 France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.3.3 France: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.3.3.1 France: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.3.4 France: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.3.5 France: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.4 Italy
  - 9.1.1.4.1 Overview
  - 9.1.1.4.2 Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.4.3 Italy: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.4.3.1 Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.4.4 Italy: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.4.5 Italy: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.5 Spain
  - 9.1.1.5.1 Overview
  - 9.1.1.5.2 Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.5.3 Spain: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.5.3.1 Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.5.4 Spain: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.5.5 Spain: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.6 Russia
  - 9.1.1.6.1 Overview
  - 9.1.1.6.2 Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.3 Russia: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.3.1 Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.4 Russia: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.5 Russia: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.7 Rest of Europe
  - 9.1.1.7.1 Overview
  - 9.1.1.7.2 Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.7.3 Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.7.3.1 Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.7.4 Rest of Europe: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.7.5 Rest of Europe: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

10. Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in Europe Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Advanz Pharma Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms